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Using transcriptomic gene expression proﬁling we found tumor suppressor DRO1 being repressed in
AIB1 transgenic mice. In agreement, AIB1 represses DRO1 promoter and its expression levels inver-
sely correlate with DRO1 in several cancer cell lines and in ectopic and silencing assays. Estrogen
modulators treatment showed a regulation in an estrogen receptor-dependent fashion. Importantly,
DRO1 overexpression resulted in BCLAF1 upregulation, a compelling concept given that BCLAF1 is a
death-promoting transcriptional repressor. Additionally, DRO1 shuttles from Golgi to the endoplas-
mic reticulum upon apoptotic stimuli, where it is predicted to facilitate the apoptosis cascade.
Finally, DRO1 repression is an important factor for AIB1-mediated inhibition of apoptosis. Collec-
tively, our results reveal DRO1 as an AIB1-targeted tumor suppressor, providing a novel mechanism
for AIB1-dependent inhibition of apoptosis.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction was rather too low, about 40 kDa, indicating the crossreactivity ofImproper balance between cell proliferation and apoptosis is a
hallmark of cancer. During tumor progression, oncogene activation
combines with loss of suppressor function to escape from senes-
cence and apoptosis, providing advantages to affected cells. This
combination can be acquired in sequential steps or directly by a
single modiﬁcation that inhibits compensatory tumour-suppres-
sive responses. Elucidating the pathways underlying an oncogene
or tumor suppressor is a key to ﬁnd new strategies for improving
cancer therapy.
The gene coiled-coil domain containing 80 (i.e. CCDC80, also
called DRO1, URB, SSG1 and equarin) was identiﬁed as upregulated
in brown adipose tissue of mice deﬁcient in bombesin receptor sub-
type-3 [1]. Furtherstudies revealed tobeabundantlyexpressed in fat
and deregulated in obesity [2], regulating adipogenesis through the
down-regulation of Wnt/b-catenin signalling and induction of C/
EBPa and PPARc [3]. In addition, DRO1 is also expressed in dermal
papilla cells [4], in bone marrow stromal cells and during develop-
ment suggesting a role in skeletogenesis [5] and in eye formation
[6]. The expression of DRO1mRNAwas also identiﬁed as down-reg-
ulatedby17b-estradiol in the ratuterus [7], althoughproteinwas in-
creased in the mammary gland of treated rats. However, the
molecular weight of the protein analyzed in these experimentschemical Societies. Published by E
epartment of Otolaryngology,antibodies with other molecular species or the detection of a sub-
product. Interestingly, DRO1was found to sensitize cells to induced
apoptosis and its expression was highly reduced in colon and pan-
creatic cancers [8], revealing its role as a tumor suppressor.
AIB1 is an oncogene that functions as a transcriptional coactiva-
tor in the nucleus [9,10]. Nuclear shuttling of AIB1 correlates with
cell cycle progression in non-cancer cells [11], but this distribution
is altered in cancer cell lines [12]. AIB1 overexpression occurs in
many types of tumors (reviewed in [13]) and this is also the cause
of cancer in animal models [14]. Noteworthy, an oncogenic isoform
of AIB1 lacking the nuclear localization signal (AIB1-Delta3) local-
izes in the cytosol and controls cytoskeletal organization and cell
migration [15]. Most of the work done to characterize AIB1 onco-
genic-dependent pathways has lead to the identiﬁcation of other
oncogenes that help to explain AIB1 pathology. High levels of AIB1
stimulate invasiveness and correlates with high levels of Twist
[16]. In addition, AIB1 promotes G1 progression by coactivating
the transcription of E2F1 [17]. AIB1 also functions as an AP-1 coacti-
vator to upregulate the expression of MMP7 and MMP10 in breast
cancer cell lines [18]. Similarly, in prostate cancer cell lines AIB1
overexpression enhances coactivation of the transcription factors
PEA3 (an Ets family member) and AP-1, thus increasing the levels
of MMP2 and MMP13 and resulting in greater ability to migrate
[18]. These different expression patterns suggest that AIB1-induced
MMP expression depends on the cellular context. Moreover, AIB1
regulates the expression ofMMP2andMMP9 throughPEA3 transac-
tivation activity [19]. AIB1 has also been associated with ER81, an-
other member of the Ets family, to stimulate the expression oflsevier B.V. All rights reserved.
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pression can promote cancer initiation and progression through the
synergistic action of additional alterations. However, little is known
about the link between AIB1 and tumor suppressors.
2. Materials and methods
2.1. Cell cultures and procedure
Human mammary epithelial cells (HMEC, Cambrex) were
grown in MEBM media supplemented with MEGM growth
requirements (Clonetics). All other cell lines were grown in DMEM
supplemented with 10% FBS. HMECs were infected at 40 MOI with
Ad5-adenovirus to express human AIB1 or green ﬂuorescent pro-
tein (GFP) as control. Fourty nanometers Stealth siRNA (Invitrogen)
targeting AIB1 or DRO1 mRNA were transfected using Lipofect-
amine 2000 (Invitrogen) according to the manufacturer’s instruc-
tions. DNA transfections were performed with Lipofectamine LTX
reagent (Invitrogen) according to company speciﬁcations. Cells
were harvested 48 h post-transfection or infection. For the stimu-
lation with estrogen modulators, MCF-7 cells were grown for a
week in DMEM phenol-red-free medium plus 10% charcoal and
dextran-treated FBS (HyClone). At time 0 cells were stimulated
either with 10 nM 17b-estradiol, 10 lM 4-hydroxytamoxifen (Sig-
ma) or 1 lM ICI 182780 (AstraZeneca Pharmaceuticals). DRO1 har-
boring the Flag epitope at the C-terminus was cloned under the
doxycycline-inducible promoter pTRE2hyg and transfected in
Tet-On inducible MCF-7 cells (Clontech). Cells were grown in the
presence of 100 lg/mL G418 (Sigma) and 100 lg/mL hygromycin
B (Invitrogen). DRO1 expression was induced with 10 lg/mL doxy-
cycline (Sigma) at least 48 h before each experiment.Fig. 1. AIB1 negatively regulates DRO1 mRNA levels. (A) HMEC were infected with adeno
mRNA levels were quantiﬁed by qRT-PCR. Values were normalized against GAPDH levels
(B) MCF-7 cells were transfected with control siRNA (h) or with speciﬁc AIB1 siRNA (j).
of three replicates from three independent experiments ± SE. Western blotting in the inse
deprived for a week and further stimulated with 10 nM 17-b-estradiol. Total RNA was isol
are western blots against DRO1 and b-actin as loading control of MCF-7 cells grow
experiments ± SE. (D) Different human cancer cell lines and primary non-cancerous HMEC
were quantiﬁed by qRT-PCR and normalized against GAPDH according to Pfafﬂ’s equati
determined in U2OS cells transfected with 500 ng vector alone (Control) or containin
replicates ± SE. Signiﬁcative values are indicated ⁄P = 0.016.2.2. Reverse transcription and quantitative real-time PCR
Total RNA was isolated using TRIzol (Invitrogen) reagent. For
BCLAF1 cDNA synthesis followed by quantitative real-time PCR
(qRT-PCR) was performed following manufacturer’s protocol
(SABioscience RT2 qPCR) using HPRT1 as housekeeping gene. For
the rest of genes, cDNA was synthesized with SuperScript First-
Strand (Invitrogen) and quantiﬁed with a standard SYBR green
PCR kit (Eurogen). Primers used were: DRO1 50 TAT-
GTGCAACAACGTGATGA 30 and 50 AAGTGGTCGATTTTCATGGT 30;
AIB1 50 GGCCAGTGATTCACGAAAACG 30 and 50 ACTTTCCTGCTCC-
CGTCTCC 30; GAPDH as housekeeping gene 50 ACCACAGTCCATGC-
CATCAC 30 and 50 TCCACCACCCTGTTGCTGTA 30.
2.3. Cell apoptosis analysis by ﬂow cytometry
MCF-7-TetOn cells were treated for 6 h with 1 lM stauro-
sporine (Sigma) to induce apoptosis. Cells were trypsinized,
washed with PBS and 250  103 cells were centrifuged at 200g
for 5 min and further ﬁxed in 1 ml 70% ethanol at 20 C for
16 h. Cells were stained overnight in 250 lL PBS containing
50 lg/mL propidium iodine and 1 ng/mL RNase (Roche) and ana-
lyzed in a Cytomics FC500 (Beckman Coulter). TUNEL assay was
performed with cell death detection kit (Roche). Staurosporine
was maintained for 19 h in cells analyzed by ﬂow cytometry.
2.4. Vector construction and luciferase assays
DRO1 cDNA was ampliﬁed from HeLa cells by RT-PCR with oli-
gos 50 ACACAATGACATGGAGAATGG 30 y 50 GCAGCTGCAGAGGAA-
ACTG 30 and Flag sequence was further added at the C-terminusvirus expressing vectors (Ad-GFP, h; Ad-AIB1, j) and two days later relative DRO1
and represent the mean value of three experiments ± standard error (SE). ⁄P < 0.01.
Relative DRO1 mRNA levels were quantifyed 2 days later. Values represent the mean
ts show AIB1 levels for each of the conditions tested. (C) MCF-7 cells were estrogen
ated at the indicated times and relative DRO1 mRNA levels were determined. Inserts
n in the presence (+E2) or absence (E2) of estradiol. Mean values of three
were grown under standard conditions. DRO1 mRNA levels (j) and AIB1 levels (h)
on. Bars represent mean values of four replicates ± SE. (E) DRO1 mRNA levels were
g either of the oncogenes v-H-ras, v-Src or Erbb2. Bars are mean values of four
Fig. 2. Transcriptional regulation of DRO1 promoter by AIB1. (A) Schematic representation of DRO1 promoter and reporter constructs. Arrow indicates the transcriptional
start site; black box corresponds to the promoter region and white box corresponds to transcribed DRO1 that includes the ﬁrst intron and part of the second exon. (B) COS1
cells were transfected with the indicated genomic regions of DRO1 gene and cotransfected with AIB1 or pCDNA3.1 empty vector. Luciferase activities were normalized for
transfection efﬁciency by renilla activities. Values represent fold activation over vector without AIB1. ⁄P = 0.02. (C) Fragments of the distal promoter region were obtained by
PCR and analyzed as in (B). Values represent fold activation over vector without AIB1.⁄P = 0.01. (D) MCF-7 cells were silenced with interference RNA for AIB1 (+) or RNAi
control () and one day later were transfected with same reporter constructs as in (C). Two days later luciferase assay was determined as in (B). Values represent fold
activation over control RNAi. ⁄P = 0.0001.
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30 and 50 GCGCGAATTCTCACTTGTCGTCATCGTCCTTGTAGTCGT-
AAGGGTATCCATG 30. The resulting amplicon was cloned into
XhoI/EcoRI sites of pcDNA3.1- and sequenced for validation.
DRO1 promoter regions were ampliﬁed from U2-OS genomic
DNA with the following oligos: (4813, 2134) 50 CTA-
CAAGGTTTCCCCAGCAA 30 and 50 GGGCTTCAGAAAATCCTCCT 30;
(2094, 1) 50 AAGCCCCACTTTGCCAGTGT 30 and 50 GAG-
TGAGAAGGCTGTTCTTTG 30; (+5, +1829) 50 CTGAGTCCACTCT-
GAACGTGCT 30 and 50 TTCTCACCTTGCCTCCTTCCT 30 and
subcloned as KpnI/NheI; NheI/BglII and BglII/HindIII fragments,
respectively in the pGL3 basic Luciferase vector (Promega). One
day before transfection 50  103 COS1 cells were seeded in sextu-
plicates in six well plates. Each transfection contained 500 ng pGL3
basic vector harbouring each of the promoter inserts or empty vec-
tor, 100 ng pcDNA 3.1-AIB1 or empty vector and 30 ng pRL-TK as
internal control. Luciferase and renilla assays (Promega) were done
48 h after transfection.
2.5. Western blot and immunoﬂuorescence
Cell lysates were done with commercial lysis buffer (Cell Signal-
ing) supplemented with protease cocktail inhibitors (Roche),
150 mM NaCl, 1 mM AEBSF (Roche), and 1 mM NaF. Lysates were
centrifuged at 14,000 rpm for 15 min. Thirty micrograms of protein
was resolved on SDS–PAGE gel and transferred to PVDF mem-
branes. For immunoﬂuorescence, cells were grown on cover slips.
Colocalization with subcellular compartments was performed with
Organelle lights (Invitrogen) 24 h after baculovirus infection. Cells
were ﬁxed, and stained with anti-Flag antibodies (Sigma) followedby anti-mouse antibodies coupled to Cy3 (Jackson ImmunoRe-
search), mounted with ﬂuorescent mounting media (Dako) and
visualized with a ﬂuorescent microscope. DRO1 antibodies were
generated by immunizing rabbits with peptides corresponding to
amino acids 313–328 and 935–950 of human DRO1 sequence.
3. Results and discussion
3.1. Down-regulation of DRO1 by AIB1
Most of the work done to explain AIB1 oncogenic potential has
lead to the intervention of other oncogenes and oncogenic path-
ways. The mechanisms of AIB1 to promote cancer initiation, pro-
gression, and endocrine resistance involve a variety of signaling
pathways, including ER, IGF/PI3K/AKT, HER2, NF-jB and Ets as well
as cell cycle regulation (reviewed in [21]). AIB1 is also an in vivo
transducer of H-Ras-induced tumors [22]. Using high-density gen-
ome-wide expression microarrays to analyze the differential
expression of genes we detected a signiﬁcant down-regulation of
DRO1 in transgenic mouse mammary epithelial cells overexpress-
ing AIB1 (Fig. S1 and Tables S1 and S2). Since DRO1 has been re-
ported to be a tumor suppressor with pro-apoptotic
characteristics, we thought this ﬁnding of interest and ﬁrst focused
to demonstrate the array results. Overexpression of AIB1 in human
primary cultures (HMECs) potently inhibited DRO1 mRNA levels
(Fig. 1A), supporting the role of AIB1 as a negative regulator for
DRO1. In addition, silencing the expression of AIB1 in MCF-7 cells,
a human mammary carcinoma that overexpresses AIB1, resulted in
a signiﬁcant increase in DRO1 levels (Fig. 1B), suggesting that
DRO1 is repressed in MCF-7 by AIB1. Moreover, stimulation of
Fig. 3. Ectopic expression of DRO1 co-localizes with Golgi compartment and cellular perimeter. (A) Expression of Flag-DRO1 was induced by doxycycline treatment in Tet-On
inducible MCF-7 cells. Cultures were further infected with GFP constructs targeting speciﬁc subcellular structures as indicated in each panel. DRO1 was visualized with anti-
Flag antibodies, followed by incubation with Cy3-conjugated donkey anti-mouse antibodies. Scale bar: 10 lm. Flag-DRO1 staining around the perimeter of the cell is
indicated with arrows. (B) Conditioned media from doxycycline-stimulated cells for the indicated times were analyzed by western blot with DRO1 antibodies. Protease
inhibitors (Roche) were added (+) or not () for the last 24 h to prevent DRO1 proteolysis and potentiate DRO1 signal [3]. (C) Fold increase in BCLAF1 expression was
determined after doxycycline treatment for 3 days in MCF-7 cells harboring the DRO1 inducible vector (pTRE2hygDRO1) or in the parental cell line lacking it (). Bars
represent mean values of three independent experiments ± SE, P < 0.05.
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through time, whereas treatment with anti-estrogens (tamoxifen
or ICI182780) increased DRO1 levels (Fig. 1C). These results sug-
gest that AIB1 as well as the estrogen receptor repress DRO1 and
conﬁrm our initial ﬁndings in AIB1 transgenic mice.
We further quantiﬁed DRO1 expression in different cancer cell
lines and compared them to AIB1. Although there are big variations
in DRO1-expression levels among the different cancer cell lines
tested, we noticed that many of them show an inverse correlation
between AIB1 and DRO1 expression levels (Fig. 1D). In general,
these data further support a new role for AIB1 as a negative regu-
lator of DRO1 expression. DRO1 is repressed in colorectal carcino-
mas [8] and AIB1 overexpression correlates with clinical stage of
human colorectal carcinoma [23]. However, the lung cancer cell
line H1299 shows very low levels of either of them and the ratio
in A-549 is also lower than in other cell lines, suggesting that
DRO1 expression is also affected by genes other than AIB1. In fact,
DRO1 expression was markedly decreased after neoplastic trans-
formation by b-catenin or K-Ras [8]. In agreement with the down-
regulation of DRO1 by oncogenes, transfection of v-H-Ras, v-Src
and Erbb2 resulted in decreased DRO1 levels (Fig. 1E), conﬁrming
that multiple oncogenes modulate DRO1 expression. Based in
DRO1 pro-apoptotic function, our results support that DRO1 mayconstitute a novel mechanism to explain AIB1 inhibition of apopto-
sis [14].
3.2. Promoter analysis of DRO1
To further study and map DRO1 regulatory elements affected by
AIB1, we cloned sequential regions of its promoter and analyzed
them in a luciferase reporter assay. As shown in the schematic rep-
resentation in Fig. 2A, we evaluated a distal region to the start of
transcription (4813, 2134); a proximal region (2094, 1)
and a transcribed region containing the ﬁrst intron (+5, +1829).
The last two regions showed a relatively higher activity when
cotransfected with AIB1 (Fig. 2B), which may be due to the pres-
ence of several responsive elements for transcription factors for
which AIB1 is a coactivator. For instance, there are several poten-
tial binding sites for NF-jB and Pax-2. Noteworthy, the distal pro-
moter region displayed a signiﬁcant decrease in the transcriptional
activity when cotransfected with AIB1, supporting to contain the
regulatory elements that down-regulate DRO1. Further promoter
analysis with more detailed constructs to nail down the region of
interest delimited AIB1 regulatory domain to (4813/3795)
(Fig. 2C). Conversingly, silencing AIB1 in MCF-7 cells resulted in in-
creased reporter activity when transfected speciﬁcally with
Fig. 4. Induced apoptosis promotes DRO1 translocation to the endoplasmic reticulum. (A) Subconﬂuent Tet-On inducible MCF-7 cells were grown in the presence (+) or
absence () of 10 lM doxycyclin for 4 days to induce DRO1 expression. Cells were further treated with 1 lM staurosporine (+) for 6 h to induce apoptosis. Cultures were
analyzed by ﬂow cytometry and the percentage of the sub-G0/G1 fraction was quantiﬁed to estimate the ratio of apoptosis (graphic on the left). Bars represent mean values of
three replicates ± SE, ⁄P = 0.002; ⁄⁄P = 0.001. Increase in apoptosis after staurosporine treatment and/or induced DRO1 expression was also conﬁrmed by TUNEL (bottom
panels right). (B) GFP-expressing cells in different subcellular compartments reveal translocation of DRO1 from Golgi to the endoplasmic reticulum after staurosporine
treatment. (C) AIB1 expression alone or in combination with DRO1 was silenced as indicated in MCF-7 cells. Cells were further treated with staurosporine and sub-G0/G1
population was calculated by ﬂow cytometry and referred to levels without staurosporine. Bars represent mean values of three independent experiments ± SE, ⁄P = 0.004;
⁄⁄P = 0.002. Western blot analysis was done in parallel to demonstrate AIB1 and DRO1 expression levels under the same conditions.
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latory domain for AIB1.
3.3. DRO1 colocalizes in Golgi and at the plasmatic membrane
Previous studies indicated that DRO1 is a secreted protein
[3,5,6] that is also found in the extracellular matrix [24]. However,
these results are partially controversial with other authors that
localized DRO1 in the cytosol [7] or that could not detect DRO1
at the membrane or weakly in the secretory pathway [8]. To re-
solve this question we generated a doxycycline inducible cell line
for the expression of DRO1. MCF-7-TetOn cells expressing DRO1-
Flag were further infected with viruses to express GFP speciﬁcally
at selected subcellular compartments. Our results in Fig. 3 clearly
demonstrate that DRO1 is localized at the Golgi apparatus. When
induction of DRO1-Flag expression was prolonged for 10 days,
DRO1 could also be detected at the cytoplasmic membrane
(Fig. 3A, right bottom panel). DRO1 was also detected in the condi-
tioned media 7 days after doxycycline treatment (Fig. 3B), thus
conﬁrming to be a secretory protein that can also be retained at
the cell surface when overexpressed. In addition, based in previous
report supporting a role for DRO1 in apoptosis [8] we performed aPCR array analysis (RT2 Proﬁler Human Apoptosis, PAHS-012F-2;
SABiosciences). Importantly, overexpression of DRO1 resulted in
signiﬁcant increase of BCLAF1 expression (Fig. 3C), which may ex-
plain in part the increased sensibility to apoptotic stimuli when
DRO1 is overexpressed [8].
3.4. AIB1 inhibition of apoptosis is partly dependent in DRO1
repression
In order to study the contribution of DRO1 in apoptosis we ana-
lyzed DRO1-Flag inducible cells after staurosporine treatment.
Staurosporine induced highest apoptosis in DRO1-Flag expressing
cells, as determined by TUNEL assay and in sub-G0/G1 population
by ﬂow cytometry analysis (Fig. 4A). Interestingly, ectopic expres-
sion of DRO1 colocalizes abundantly in Golgi but is potently dis-
placed from Golgi upon apoptotic stimuli (Fig. 4B, compare left
and right panels). Induced apoptosis by staurosporine implies the
cross-talk between two apoptotic pathways and is accelerated
when caspase 3 is expressed in MCF-7 cells [25,26]. This mecha-
nism is mediated by translocation of BAX to the mitochondria
and the release of cytochrome c. However, DRO1 did not shuttle
to mitochondria under these conditions but was instead retained
3046 J. Ferragud et al. / FEBS Letters 585 (2011) 3041–3046in the endoplasmic reticulum (Fig. 4B), resembling the collapsed
Golgi and suggesting an endoplasmic reticulum stress-induced
apoptosis. To further analyze the contribution of DRO1 repression
in AIB1-mediated inhibition of apoptosis we silenced AIB1 alone or
together with DRO1 and further treated the cells with stauro-
sporine. As expected, silencing AIB1 resulted in increased apoptosis
which was extensively impeded by silencing DRO1 as well
(Fig. 4C). Although other pathways may also be relevant to explain
AIB1-dependent inhibition of apoptosis (i.e. overexpression of IGF-
I), our data reveals DRO1 pathway as a relevant target of AIB1 to
prevent apoptosis and provide a novel mechanism to explain
AIB1 as an oncogene.
Acknowledgements
This work was supported by grants SAF2009-08334 from Span-
ish Ministry of Science and Innovation; EVES 047/2008 from Con-
selleria de Sanitat and ACOMP/2009/001 from Consellería
d’Educació i Ciencia, both from Generalitat Valenciana. A. Pla was
supported by a pre-doctoral fellowship from the Conselleria d’Edu-
cació from Generalitat Valenciana. J De Las Rivas thanks the sup-
port provided by MICINN-ISCiii reference PS09/00843.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2011.08.025.
References
[1] Aoki, K., Sun, Y.J., Aoki, S., Wada, K. and Wada, E. (2002) Cloning, expression,
and mapping of a gene that is upregulated in adipose tissue of mice deﬁcient
in bombesin receptor subtype-3. Biochem. Biophys. Res. Commun. 290, 1282–
1288.
[2] Okada, T. et al. (2008) URB is abundantly expressed in adipose tissue and
dysregulated in obesity. Biochem. Biophys. Res. Commun. 367, 370–376.
[3] Tremblay, F., Revett, T., Huard, C., Zhang, Y., Tobin, J.F., Martinez, R.V. and
Gimeno, R.E. (2009) Bidirectional modulation of adipogenesis by the secreted
protein Ccdc80/DRO1/URB. J. Biol. Chem. 284, 8136–8147.
[4] Cha, S.Y., Sung, Y.K., Im, S., Kwack, M.H., Kim, M.K. and Kim, J.C. (2005) URB
expression in human dermal papilla cells. J. Dermatol. Sci. 39, 128–130.
[5] Liu, Y., Monticone, M., Tonachini, L., Mastrogiacomo, M., Marigo, V., Cancedda,
R. and Castagnola, P. (2004) URB expression in human bone marrow stromal
cells and during mouse development. Biochem. Biophys. Res. Commun. 322,
497–507.
[6] Mu, H., Ohta, K., Kuriyama, S., Shimada, N., Tanihara, H., Yasuda, K. and Tanaka,
H. (2003) Equarin, a novel soluble molecule expressed with polarity at chick
embryonic lens equator, is involved in eye formation. Mech. Dev. 120, 143–
155.
[7] Marcantonio, D., Chalifour, L.E., Alaoui-Jamali, M.A., Alpert, L. and Huynh, H.T.
(2001) Cloning and characterization of a novel gene that is regulated by
estrogen and is associated with mammary gland carcinogenesis.
Endocrinology 142, 2409–2418.[8] Bommer, G.T. et al. (2005) DRO1, a gene down-regulated by oncogenes,
mediates growth inhibition in colon and pancreatic cancer cells. J. Biol. Chem.
280, 7962–7975.
[9] Anzick, S.L., Kononen, J., Walker, R.L., Azorsa, D.O., Tanner, M.M., Guan, X.Y.,
Sauter, G., Kallioniemi, O.P., Trent, J.M. and Meltzer, P.S. (1997) AIB1, a steroid
receptor coactivator ampliﬁed in breast and ovarian cancer. Science 277, 965–
968.
[10] Li, H., Gomes, P.J. and Chen, J.D. (1997) RAC3, a steroid/nuclear receptor-
associated coactivator that is related to SRC-1 and TIF2. Proc. Natl. Acad. Sci.
USA 94, 8479–8484.
[11] Avivar, A., Garcia-Macias, M.C., Ascaso, E., Herrera, G., O’Connor, J.E. and de
Mora, J.F. (2006) Moderate overexpression of AIB1 triggers pre-neoplastic
changes in mammary epithelium. FEBS Lett. 580, 5222–5226.
[12] Ferrero, M., Avivar, A., Garcia-Macias, M.C. and de Mora, J.F. (2008)
Phosphoinositide 3-kinase/AKT signaling can promote AIB1 stability
independently of GSK3 phosphorylation. Cancer Res. 68, 5450–5459.
[13] Gojis, O., Rudraraju, B., Alifrangis, C., Krell, J., Libalova, P. and Palmieri, C.
(2010) The role of steroid receptor coactivator-3 (SRC-3) in human malignant
disease. Eur. J. Surg. Oncol. 36, 224–229.
[14] Torres-Arzayus, M.I., Font de Mora, J., Yuan, J., Vazquez, F., Bronson, R., Rue, M.,
Sellers, W.R. and Brown, M. (2004) High tumor incidence and activation of the
PI3K/AKT pathway in transgenic mice deﬁne AIB1 as an oncogene. Cancer Cell
6, 263–274.
[15] Long, W., Yi, P., Amazit, L., LaMarca, H.L., Ashcroft, F., Kumar, R., Mancini, M.A.,
Tsai, S.Y., Tsai, M.J. and O’Malley, B.W. (2010) SRC-3Delta4 mediates the
interaction of EGFR with FAK to promote cell migration. Mol. Cell. 37, 321–
332.
[16] Kajiro, M. et al. (2009) The ubiquitin ligase CHIP acts as an upstream regulator
of oncogenic pathways. Nat. Cell. Biol. 11, 312–319.
[17] Louie, M.C., Zou, J.X., Rabinovich, A. and Chen, H.W. (2004) ACTR/AIB1
functions as an E2F1 coactivator to promote breast cancer cell proliferation
and antiestrogen resistance. Mol. Cell. Biol. 24, 5157–5171.
[18] Yan, J., Erdem, H., Li, R., Cai, Y., Ayala, G., Ittmann, M., Yu-Lee, L.Y., Tsai, S.Y. and
Tsai, M.J. (2008) Steroid receptor coactivator-3/AIB1 promotes cell migration
and invasiveness through focal adhesion turnover and matrix
metalloproteinase expression. Cancer Res. 68, 5460–5468.
[19] Qin, L., Liao, L., Redmond, A., Young, L., Yuan, Y., Chen, H., O’Malley, B.W. and
Xu, J. (2008) The AIB1 oncogene promotes breast cancer metastasis by
activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9
expression. Mol. Cell. Biol. 28, 5937–5950.
[20] Goel, A. and Janknecht, R. (2004) Concerted activation of ETS protein ER81 by
p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase
HER2/Neu. J. Biol. Chem. 279, 14909–14916.
[21] Lahusen, T., Fereshteh, M., Oh, A., Wellstein, A. and Riegel, A.T. (2007)
Epidermal growth factor receptor tyrosine phosphorylation and signaling
controlled by a nuclear receptor coactivator, ampliﬁed in breast cancer 1.
Cancer Res. 67, 7256–7265.
[22] Kuang, S.Q., Liao, L., Zhang, H., Lee, A.V., O’Malley, B.W. and Xu, J. (2004) AIB1/
SRC-3 deﬁciency affects insulin-like growth factor I signaling pathway and
suppresses v-Ha-ras-induced breast cancer initiation and progression in mice.
Cancer Res. 64, 1875–1885.
[23] Xie, D., Sham, J.S., Zeng, W.F., Lin, H.L., Bi, J., Che, L.H., Hu, L., Zeng, Y.X. and
Guan, X.Y. (2005) Correlation of AIB1 overexpression with advanced clinical
stage of human colorectal carcinoma. Hum. Pathol. 36, 777–783.
[24] Manabe, R. et al. (2008) Transcriptome-based systematic identiﬁcation of
extracellular matrix proteins. Proc. Natl. Acad. Sci. USA 105, 12849–12854.
[25] Tang, D., Lahti, J.M. and Kidd, V.J. (2000) Caspase-8 activation and bid cleavage
contribute to MCF7 cellular execution in a caspase-3-dependent manner
during staurosporine-mediated apoptosis. J. Biol. Chem. 275, 9303–9307.
[26] Xue, L.Y., Chiu, S.M. and Oleinick, N.L. (2003) Staurosporine-induced death of
MCF-7 human breast cancer cells: a distinction between caspase-3-dependent
steps of apoptosis and the critical lethal lesions. Exp. Cell. Res. 283, 135–145.
